VivoSeq
Psychiatry

Major Depressive Disorder (MDD)

8

Pipeline Programs↗

12

Active Trials↗

8

Companies Involved↗

Major Depressive Disorder (MDD) is an early-stage landscape with 8 programs across 8 companies. The most active players are Seaport Therapeutics, Clexio Biosciences Ltd., Draig Therapeutics Ltd. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

41/100

Pipeline Velocity

34/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Seaport Therapeutics

1 program

Phase 2C

Clexio Biosciences Ltd.

1 program

Phase 2D

Draig Therapeutics Ltd

1 program

Phase 2Ono Pharmaceutical Co. Ltd logo

Ono Pharmaceutical Co. Ltd

1 program

Phase 2A

ACADIA Pharmaceuticals Inc.

1 program

Phase 2Eli Lilly logo

Eli Lilly

2 programs

Phase 2

Pipeline

Programs by Phase

Analysis

Trial Status

15

clinical trials

Recruiting9 · 60%
Completed3 · 20%
Not yet recruiting2 · 13%
Enrolling by invitation1 · 7%

Clinical Trials

Trial Activity

15 trials

A Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Study of ACP-211 Monotherapy in Adults With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
Recruiting·AACADIA Pharmaceuticals Inc.·Phase 2·NCT07284667·153 enrolled
A Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Monotherapy Study of the Efficacy, Safety, and Tolerability of SPT-300 in Adults With Major Depressive Disorder (MDD), With or Without Anxious Distress
Recruiting·SSeaport Therapeutics·Phase 2·NCT07065240·360 enrolled
Predictors of Early Relapse During Follow-up Of Remitted Major Depression
Recruiting·—·N/A·NCT06746155·252 enrolled
Effects of Full-Spectrum Cannabidiol Oil on Symptoms of Treatment-Resistant Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial
Recruiting·UUniversidade do Sul de Santa Catarina·Preclinical·NCT07696871·120 enrolled
Repeated Real-time Biofeedback With 7-Tesla MRI for Treatment of Depression
Recruiting·UUniversity of Oxford·Preclinical·NCT07694076·60 enrolled
Efficacy of Bright Light Therapy on Cognitive Impairment in Major Depressive Disorder and Its Neuroimaging Mechanisms: Protocol for a Randomised Controlled Trial
Recruiting·PPeking University Sixth Hospital·Preclinical·NCT07508215·120 enrolled
A Phase 2 Double-blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of DT-101 in Adults With Major Depressive Disorder (MDD)
Recruiting·DDraig Therapeutics Ltd·Phase 2·NCT07300969·300 enrolled
An Efficacy and Safety, Phase III, Multi-center, Double-Blind, Randomized Controlled Study Comparing 2 Active Doses of CYB003 and Placebo in Eligible Participants With Major Depressive Disorder
Recruiting·CCybin IRL Limited·Phase 3·NCT06793397·330 enrolled
Examining the Effects of Escitalopram and Memantine on Pattern Separation in Major Depressive Disorder
Recruiting·—·Phase 1·NCT07139834·30 enrolled
Imaging- vs. Scalp-Targeted Accelerated TMS for Depression: The Number Needed to Scan Trial
Not yet recruiting·BBrigham and Women's Hospital·Preclinical·NCT07043738·160 enrolled
Regulated Stimulation for Optimized Network Activity and Therapeutic Equilibrium - Maintenance
Not yet recruiting·MMotif Neurotech, Inc.·Preclinical·NCT07684794·10 enrolled
A 6-Week, Multicenter, Open-Label, Monotherapy, Extension Study of SPT-300 in Adults With Major Depressive Disorder, With or Without Anxious Distress
Enrolling by invitation·SSeaport Therapeutics·Phase 2·NCT07161700·360 enrolled
A Multicenter Randomized Double-Blind Controlled Trial of Six-Week Transcranial Temporal Interference Stimulation（TIS） Targeting the Right Amygdala for Rapid Alleviation of Depressive Symptoms.
Completed·RRuijin Hospital·Preclinical·NCT07059143·38 enrolled
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group, Multi-center Trial to Evaluate the Efficacy and Safety of ONO-1110 in Patients With Major Depressive Disorder
Completed·Ono Pharmaceutical Co. Ltd logoOno Pharmaceutical Co. Ltd·Phase 2·NCT06792136·103 enrolled
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Design, Phase 2 Study to Assess the Efficacy and Safety of CLE-100 as an Adjunctive Treatment for Major Depressive Disorder Patients With Inadequate Response to Standard Antidepressants
Completed·CClexio Biosciences Ltd.·Phase 2·NCT06340958·99 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)